PI
ARIA

Putnam Investments’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

Putnam Investments’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-7,822,704
Closed -$97.3M – 1340
2016
Q4 		$97.3M Buy
7,822,704
+878,205
+13% +$10.6M 0.23% 115
2016
Q3 		$95.1M Sell
6,944,499
-8,200,046
-54% -$82.3M 0.23% 118
2016
Q2 		$112M Sell
15,144,545
-3,184,115
-17% -$23.9M 0.27% 98
2016
Q1 		$117M Buy
18,328,660
+2,653,238
+17% +$14.9M 0.28% 85
2015
Q4 		$98M Sell
15,675,422
-4,871,079
-24% -$32M 0.22% 100
2015
Q3 		$120M Buy
20,546,501
+11,221,314
+120% +$86.4M 0.27% 88
2015
Q2 		$77.1M Sell
9,325,187
-1,231,506
-12% -$10.9M 0.15% 150
2015
Q1 		$87M Buy
10,556,693
+7,275,773
+222% +$53.8M 0.17% 125
2014
Q4 		$22.5M Buy
3,280,920
+3,007,431
+1,100% +$18.8M 0.05% 322
2014
Q3 		$1.48M Buy
273,489
+3,775
+1% +$22K ﹤0.01% 1110
2014
Q2 		$1.72M Buy
269,714
+677
+0.3% +$4.66K ﹤0.01% 1066
2014
Q1 		$2.17M Sell
269,037
-12,057
-4% -$93.9K ﹤0.01% 1032
2013
Q4 		$1.92M Buy
+281,094
New +$1.52M ﹤0.01% 1060

Other funds holding ARIA

FPF
FNY Partners Fund New York $185M AUM 32.57% 1-Year Est. Return

Putnam Investments's ARIA Position: Q1 2017 in Review

Putnam Investments sold out of Ariad Pharmaceuticals Inc (ARIA) in Q1 2017, closing a stake of 7,822,704 shares — an estimated $97.3M sold.

Putnam Investments first reported a position in ARIA in Q4 2013 and held it in 13 quarters. The position peaked at $120M in Q3 2015. 1 fund tracked by Wall St. Rank holds ARIA as of Q1 2017.

  • Putnam Investments reported no remaining Ariad Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
  • Putnam Investments sold 7,822,704 Ariad Pharmaceuticals Inc shares in Q1 2017, an estimated $97.3M.
  • Putnam Investments first reported a position in Ariad Pharmaceuticals Inc in Q4 2013 and held it in 13 quarters.
  • Putnam Investments's Ariad Pharmaceuticals Inc position peaked at $120M in Q3 2015.
  • 1 fund tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q1 2017.

Based on Putnam Investments's 13F filing for Q1 2017, filed 15 May 2017.